Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) has announced that its clinical facility in Mexico City has initiated patient recruitment for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens. Unlike the first group, which focused solely on safety, Group Two will evaluate both safety and near-and distance-vision performance. The surgeries are targeted for Fall 2026, marking a significant step forward in the company's clinical development programme.

Key Points

  • Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) is a Calgary, Alberta-based ophthalmic technology developer
  • Patient recruitment has begun in Mexico City for Group Two surgeries, targeted for Fall 2026
  • Group Two will assess safety plus near-and distance-vision performance using the latest-generation Ocumetics Lens and enhanced delivery system
  • Investors may be watching for 12-month follow-up data from Group One patients, currently in progress

Group Two Study Expands Scope Beyond Group One Safety Focus

The Mexico City clinical facility, which performed Group One surgeries in Fall 2025, has begun identifying and recruiting eligible patients for the upcoming Fall 2026 procedures. The announcement states that Group Two's primary and secondary purposes are to study safety, distance vision, and near vision performance of the Ocumetics Lens — a broader mandate than Group One, which focused solely on safety. President and CEO Dean Burns noted in the release that recruiting will be completed shortly, with surgical dates to be scheduled thereafter.

Next-Generation Ocumetics Lens and Enhanced Delivery System to Be Used

Group Two patients will receive Ocumetics' latest-generation accommodating intraocular lens, incorporating the company's most recent design advancements. The release states the Ocumetics Lens will be implanted using the company's enhanced lens delivery system. The company describes this combination as representing the continued evolution of its technology and its commitment to developing a differentiated solution for patients seeking improved vision across a broader range of distances. Financial terms associated with the clinical programme were not disclosed in the announcement.

Group One Outcomes Met and Exceeded Company Expectations

The release states that Group One clinical outcomes met and exceeded Ocumetics' expectations regarding the safety, performance, and handling of the Ocumetics Lens. Patients from Group One have continued to be monitored as part of the company's ongoing clinical evaluation. Twelve-month follow-up visits, which the company describes as an important study milestone, are currently in progress. Burns highlighted in the release that this longer-term data will form an important body of clinical evidence as the company advances its technology and broader development programme.